NLS Pharmaceutics Stock (NASDAQ:NLSP)
Previous Close
$4.89
52W Range
$4.08 - $40.60
50D Avg
$6.48
200D Avg
$9.99
Market Cap
$5.94M
Avg Vol (3M)
$73.96K
Beta
-0.58
Div Yield
-
NLSP Company Profile
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
NLSP Performance
Peer Comparison
Ticker | Company |
---|---|
ACHL | Achilles Therapeutics plc |
LIXT | Lixte Biotechnology Holdings, Inc. |
KTTA | Pasithea Therapeutics Corp. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
CTMX | CytomX Therapeutics, Inc. |
QNRX | Quoin Pharmaceuticals, Ltd. |
HCWB | HCW Biologics Inc. |
ASMB | Assembly Biosciences, Inc. |
RZLT | Rezolute, Inc. |
INDP | Indaptus Therapeutics, Inc. |
NRBO | NeuroBo Pharmaceuticals, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
MOLN | Molecular Partners AG |
PTIX | Protagenic Therapeutics, Inc. |
NLTX | Neurogene Inc. |
TIL | Instil Bio, Inc. |
ELYM | Eliem Therapeutics, Inc. |